How many Re2O sessions do you need?
“Isn’t Re2O a set of three?” Plenty of pages say so, but nobody quite explains where the number comes from. Here is exactly how Miso Clinic decides.
The short answer
Re2O has no clinical trial protocol that fixed a session count. The only human study (20 people, 20 weeks) was done after launch, and the “three-session course” is a number that hardened in clinic and distributor guidance. So Miso Clinic does one session, waits four weeks or more, and decides on more from the change in texture and density. It usually settles between one and three.
Why there is no fixed count
Re2O is distributed as human tissue, not as a medical device. A device must pass a trial that fixed “how many, how far apart” to be approved; human tissue had no such step. That is what separates it from Rejuran, whose “three sessions two weeks apart” came out of a phase 3 trial.
How Miso Clinic decides
- One session first. Material into thinned skin, then watch the response for four weeks or more.
- Examine at four weeks. Texture, pores, fine lines, how make-up sits.
- More at four-week intervals if needed. Usually one to three in total.
- No prepaid bundles. Fixing three sessions up front, for a treatment with no session-comparison data, has no basis.
Where other boosters get their numbers
| Product | Sessions | Source |
|---|---|---|
| Re2O (hADM) | No fixed protocol — 1–3 by condition | Clinic judgement |
| Rejuran (PN) | Three, two weeks apart | Approval phase 3 protocol |
| GOURI (liquid PCL) | One recommended, optionally 1–2 more | Manufacturer FAQ |
| Sculptra (PLLA) | Up to four, three weeks apart | US FDA approval trial |
Which treatment fits which concern
| Concern | Treatments to consider | Why |
|---|---|---|
| One session, then see the response | Re2O, one session | No fixed count, so condition decides |
| Prefer a fixed course | Rejuran 3–4 session course | The trial set the count |
| Skin very thin, likely to need repeated supply | Re2O, 2–3 sessions | Four weeks apart, after examination |
Which treatment is “best” is decided by the state of your skin right now, not by the product. In consultation we look first at what has been lost and what is still there, before we talk about any product name.
Frequently asked questions
Does one Re2O session work?
The 20-person study did not split results by session, so neither “one is enough” nor “three are needed” can be said. That is why we do one and look.
Why four weeks?
The material needs weeks to settle and the dermis to respond. Layering before that means nobody can tell what did what. Four weeks is the minimum observation window.
Can I have GOURI at the same time?
Not the same area on the same day; the effects could not be told apart. Splitting by area or by timing is possible.
Read next
If you want to go deeper
Product page
Who wrote this
Written and reviewed by Lee Chi-Hak, MD, medical director of Miso Clinic in Daegu, South Korea. Studies are cited with their size and limitations, and where we could not find data we say so. Individual decisions need an in-person examination; this page does not replace one.
| Medical director | Lee Chi-Hak, MD |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Phone | +82-53-428-2700 |
| KakaoTalk | Miso Clinic channel |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 / Closed Sundays and public holidays |
| Treatment guides | All guides |
| Comparisons | All comparisons |
| Columns | All clinical columns |
| Reference library | All booster and device references |
References
- Re2O manufacturer material (L&C Bio) — extracellular matrix from acellular human dermis (hADM), distributed as human tissue.
- Severance Hospital group, Int J Mol Sci 2026;27(5):2193, NCT07155278 — 20 people, 20 weeks, control was hyaluronic acid alone. Conducted after launch (November 2024).
- Korean Act on Safety and Management of Human Tissue — human tissue is distributed under tissue-bank licence with no pre-market clinical trial requirement.
- US FDA guidance — micronising acellular dermis takes it beyond “minimal manipulation”.
Everything on this page is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Treatment guides · Clinical columns · Reference library · Miso Clinic home
한국어 · English